

Khaled El Emam
David Sibbald
Rodrigo Barnes

17th June 2021

kelemam@replica-analytics.com david.sibbald@aridhia.com rodrigo.barnes@aridhia.com

Agenda

Context

The demand for more robust data sharing mechanisms and technology

Research Lifecycle

2

Overview of a typical research lifecycle

Data Synthesis

3

An overview of data synthesis methods






A live demonstration of integration of data synthesis within a data sharing platform







What's so hard about data sharing?







The need for proportionality



Governance Requirements

Institution ethics and governance

Patient consent and engagement

Where is data

Legal requirements GDPR as a benchmark

Administrating and approval of Data Access Requests



Data Researchers

Clinical and Scientific Needs

Wide participation on data and insights

ouilding from others Redeposition and

Freedom to innovate ML/AI

Reproducibility of method and results

and OPEN science





Benefits of Data Sharing


01015101 0101101 0110	New business models	Faster and more innovative product development	New or enhanced customer services and experiences	More efficient or innovative manufacturing	Greater speed and visibility across supply chains	Cybersecurity or prevention of fraud
Consumer goods and retail		X			X	
Financial services	Х					Х
Travel and hospitality		Х			X	
IT and telecoms			Х			Х
Manufacturing		X		X	X	
Pharma and healthcare		$\left(\mathbf{x} \right)$			(x)	
Transport and logistics		X			X	
Energy and utilities	Х				Х	
Media and marketing		X	Х			Х
Professional services					X	Х
Government		Х			Х	

Source: MIT Technology Review Insights survey, 2020





High Investment in AIML.. But







High Investment in AIML.. But

Top challenges for Al initiatives: Ranked 1-3, where 1 is greatest challenge


	Ranked 1	Ranked 2	Ranked 3	Ranked top three
Implementation challenges	13%	14%	12%	39%
Integrating Al into the company's roles and functions	14%	13%	12%	39%
Data issues (e.g., data privacy, accessing and integrating data)	16%	13%	10%	39%
Cost of Al technologies/ solution development	13%	12%	11%	36%
Lack of skills	11%	10%	10%	31%
Challenges in measuring and proving business value	10%	11%	9%	30%

Deloitte 2018





Biggest Constraints







FAIR Principles inda

indable Accessible











FINDABLE

Making data discoverable, identifiable and searchable via the assignment of metadata and unique identifiers.



ACCESSIBLE

Available and retrievable data with access via authentication and authorisation procedures.



INTEROPERABLE

Parseable and semantically understandable data allowing the broadest possible data exchange.




REUSABLE

Accurately described data with associated provenance and well documented, easily shared usage rights.






Research Lifecycle







Synthetic data on demand




Audit and Governance Reporting






The Synthesis Process















COU1A	AGECAT	AGELE70	WHITE	MALE	вмі
United States	2	1	1	1	33.75155
United States	2	1	1	0	39.24707
United States	1	1	1	0	26.5625
United States	4	1	1	1	40.58273
United States	5	0	0	1	24.42046
United States	5	0	1	0	19.07124
United States	3	1	1	1	26.04938
United States	4	1	1	1	25.46939
			_		





Synthetic Data Uses

- Data Sharing and Data Access
 - Al and data science projects
 - Software testing
 - Proof of concept and technology evaluations
 - Open data/open science
 - Hackathons and data competitions/challenges
- Data Amplification and Data Augmentation
 - Amplifying small datasets
 - Correct bias





Privacy Risks

Dataset	Fully Synthetic Data	Original Data
Washington Hospital Data	0.0197	0.098
Canadian COVID Data	0.0086	0.034

A commonly used risk threshold = 0.09









References

- Z. Azizi, C. Zheng, L. Mosquera, L. Pilote, K. El Emam: "Replicating Secondary Studies Using Synthetic Clinical Trial Data", *BMJ Open*, 11:e043497, 2021.
- K. El Emam, L. Mosquera, E. Jonker, H. Sood: "Evaluating the Utility of Synthetic
 COVID-19 Case Data", *JAMIA Open*, 14(1):ooab012, January 2021.
- K. El Emam, L. Mosquera, and C. Zheng, "Optimizing the Synthesis of Clinical Trial Data Using Sequential Trees," *JAMIA*, 28(1): 3-13, 2021.
- K. El Emam, L. Mosquera, and J. Bass, "Evaluating Identity Disclosure Risk in Fully Synthetic Health Data: Model Development and Validation," *JMIR*, vol. 22, no. 11, Nov. 2020. [Online]. Available: https://www.jmir.org/2020/11/e23139.
- K. El Emam, L. Mosquera, and R. Hoptroff, Practical Synthetic Data Generation:
 Balancing Privacy and the Broad Availability of Data. O'Reilly, 2020.
- K. El Emam, "Seven Ways to Evaluate the Utility of Synthetic Data," IEEE Security and Privacy, July/August, 2020.





Thank you

- For more information about Replica Analytics: www.replica-analytics.com
- For more information about Aridhia:
 - www.aridhia.com
- Please contact us for more information about the integrated DRE with synthetic data generation capabilities



